

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0104				
Estimated average	e burden				
nours per respons	se 0.5				

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)									
1. Name and Address of Reporting Person* Lazar David E.	2. Date of Event Requiring Statement (Month/Day/Year)  07/06/2022			3. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTNP]					
VILLA 1, 14-43RD STREET, JUMEIRAH 2				4. Relationship of Issuer (Check	Reporting Person all applicable)	Filed(Mon	5. If Amendment, Date Original Filed(Month/Day/Year)		
DUBAI, C0 00000				Officer (give tit		6. Individ	6. Individual or Joint/Group Filing(Check Applicable Line)  — Form filed by One Reporting Person  _X_ Form filed by More than One Reporting Person		
(City) (State) (Zip)		Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)			ned		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock, par value \$0.001 1,42		421,133		D (1)					
Common Stock, par value \$0.001 43,145		,145		I	By Activist Investing LLC (1) (2) (3)				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  SEC 1473 (7-02)  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4)	2. Date Exer and Expirati (Month/Day/Ye	rcisable on Date	3. Title and A Securities Un Security (Instr. 4)	Amount of nderlying Derivative nt or Number of	4. Conversion	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)		

## **Reporting Owners**

Reporting Owner Name / Address		Relationships				
		10% Owner	Officer	Other		
Lazar David E. VILLA 1, 14-43RD STREET JUMEIRAH 2 DUBAI, C0 00000		X				
Activist Investing LLC 1185 AVENUE OF THE AMERICAS, 3RD FLOOR. NEW YORK, NY 10036				Member of 10% owner group		

### **Signatures**

/s/ David E. Lazar	07/08/2022
**Signature of Reporting Person	Date
Activist Investing LLC, By: /s/ David E. Lazar, Chief Executive Officer	07/08/2022
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This Form 3 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons").
- (2) Securities of Titan Pharmaceuticals, Inc. (the "Issuer") beneficially owned directly by Activist Investing. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the securities of the Issuer beneficially owned by Activist Investing.
- Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.